FDA — authorised 25 September 2025
- Application: NDA218881
- Marketing authorisation holder: ELI LILLY AND CO
- Local brand name: INLURIYO
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Inluriyo in United States
FDA authorised Inluriyo on 25 September 2025
Marketing authorisations
FDA
- Marketing authorisation holder: ELI LILLY AND CO
- Status: approved
Inluriyo in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Inluriyo approved in United States?
Yes. FDA authorised it on 25 September 2025; FDA has authorised it.
Who is the marketing authorisation holder for Inluriyo in United States?
ELI LILLY AND CO holds the US marketing authorisation.